Role of zoledronic acid in the prevention and treatment of osteoporosis

Taken once a year, intravenous zoledronic acid (Zol) (Reclast(®) or Aclasta(®)) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Räkel, Agnès, Boucher, Andrée, Ste-Marie, Louis-Georges
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095556/
https://www.ncbi.nlm.nih.gov/pubmed/21594000
http://dx.doi.org/10.2147/CIA.S7282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095556/
https://www.ncbi.nlm.nih.gov/pubmed/21594000
http://dx.doi.org/10.2147/CIA.S7282

Ejemplares similares